Consistent engagement with current medical literature enables clinicians to apply the latest evidence-based treatment and integrate research into clinical practice. This approach enhances patient outcomes by facilitating more effective and individualized care.

Today, we’re showcasing some of the latest dermatology-related articles published recently across medical journals. The topics in today’s rundown include eczema, psoriasis, and rosacea.

Eczema Articles

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

  • Dermatology and Therapy
  • May 2026
  • Description: Delgocitinib cream is a topical pan-Janus kinase inhibitor approved for adults with moderate to severe Chronic Hand Eczema (CHE) in the USA, Canada, European Union, and multiple other countries. Here, [the researchers] assessed the systemic exposure of twice-daily topical application of delgocitinib cream 20 mg/g in adults with moderate to severe CHE treated under normal or maximal use conditions in the DELTA 2 trial and compared with the systemic exposure in adults with moderate to severe atopic dermatitis (AD) from a delgocitinib cream phase 1 AD trial.
  • Study Details
  • Source

Prenatal Maternal Antibiotic Use Increases the Risk of Childhood Eczema: A Systematic Review and Meta-Analysis

  • Scientific Reports
  • May 2026
  • Description: This meta-analysis aimed to evaluate the impact of maternal antibiotic use (either prenatal or intrapartum) on the risk of childhood atopic dermatitis, based on cohort and case-control studies.
  • Study Details
  • Source

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

  • Dermatology and Therapy
  • May 2026
  • Description: Although Chronic Hand Eczema (CHE) is associated with substantial humanistic burden, treatment patterns and economic impact are poorly understood in the USA. Therefore, this study characterized real-world treatment patterns and economic burden among patients with moderate to severe CHE in the USA.
  • Study Details
  • Source
Psoriasis Articles

Psoriasis in Skin of Color: Clinical Presentation, Diagnostic Challenges, and Therapeutic Considerations

  • Anais Brasileiros de Dermatologia
  • May 2026
  • Description: This review synthesizes current evidence on epidemiology, clinical presentation, diagnostic pitfalls, pigmentary sequelae, psychosocial dimensions, and therapeutic options so as to support equitable, patient-centred outcomes for skin of color patients living with psoriasis.
  • Study Details
  • Source

Risankizumab Versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

  • Dermatology and Therapy
  • May 2026
  • Description: Risankizumab (RZB) and deucravacitinib (DEU) are both approved for the treatment of moderate-to-severe psoriasis. Physicians value head-to-head comparisons between available therapies to make evidence-based treatment decisions. This study evaluates the safety and efficacy of RZB compared with DEU for the treatment of patients with moderate psoriasis who have not previously received biologic treatment.
  • Study Details
  • Source

Musculoskeletal and Nail Ultrasound Findings in Children with Psoriasis: A Case-Control Study

  • Pediatric Rheumatology Online Journal
  • May 2026
  • Description: Children with psoriasis can develop juvenile psoriatic arthritis. Musculoskeletal ultrasound is a helpful imaging modality in the early recognition of joint inflammation. This pilot study aims to describe clinical and subclinical joint and nail abnormalities in children with psoriasis.
  • Study Details
  • Source
Rosacea Articles

Exploring Immune‐Related Gene and Mechanisms in Rosacea Through Transcriptome Analysis and Mendelian Randomization

  • BioMed Research International
  • May 2026
  • Description: Dysregulation of the innate and adaptive immune system is thought to be central to the pathogenesis of rosacea. However, the molecular mechanism of immune-related genes has not been extensively studied in rosacea.
  • Study Details
  • Source

Topical PEGylated Azelaic Acid Nanohybrids: A Lipid–Polymer Hydrogel System for Sustained Dermal Delivery in Rosacea Management

  • Colloids and Surfaces B: Biointerfaces
  • April 2026
  • Description: Rosacea is a chronic inflammatory disorder of the central face characterized by persistent erythema, flushing, and inflammatory papules. Azelaic acid (Az) is a first-line topical therapy for papulopustular rosacea; however, its clinical efficacy is limited by poor aqueous solubility and restricted penetration across the stratum corneum. To overcome these limitations, PEGylated lipid–polymer hybrid nanoparticles (PALPHNs) encapsulating Az were developed and optimized using a Central Composite Design.
  • Study Details
  • Source

Sphenopalatine Ganglion Radiofrequency Ablation for Severe Facial Rosacea Manifestations

  • Pain Practice
  • March 2026
  • Description: Rosacea is an inflammatory, persistent erythema that can present under several clinical subtypes. Recently, a neurogenic type of rosacea has been suggested that can be associated with chronic pain and headaches. Here [the researchers] describe a successful interventional treatment for severe, likely neurogenic rosacea associated with severe migraines previously treated using various conservative approaches.
  • Study Details
  • Source

Don’t miss our other rundown articles and sign up for alerts and stay informed on the latest published articles and guidelines.